Clinical Trials Browser

Phase 2 × Lymphoma, T-Cell, Cutaneous × pembrolizumab × Clear all

NCT05956041 2026-01-07

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Phase 2 Recruiting

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT07283822 2025-12-16

Amping up With PemJAK

Phase 2 Recruiting

DermatologicLymphoid

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT05313243 2025-03-20

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Phase 2 Recruiting

DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT03385226 2024-12-09

PORT

Phase 2 Active not recruiting

DermatologicLymphoid

Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous